Arcturus Therape Stock Price, News & Analysis

Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) announced that CEO Joseph Payne will participate in the "RNA Therapeutics in Rare Diseases" panel at the Cantor Fitzgerald Virtual Rare Disease Summit on March 29, 2022, at 2:45 p.m. ET. This event highlights Arcturus' commitment to RNA medicines, particularly in infectious disease vaccines and rare liver and respiratory diseases. The company, based in San Diego, has a diverse pipeline of mRNA vaccine programs, including those for COVID-19 and cystic fibrosis, supported by innovative delivery technologies and strategic partnerships.

Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) announced the approval of inducement stock options totaling 20,000 shares for two newly-hired employees. The options have an exercise price of $20.89 per share, aligning with the stock's closing price on March 16, 2022. These options will vest over four years, with 25% vesting after one year and the remainder monthly over the subsequent 36 months. This grant is part of the company’s efforts to attract talent as it focuses on developing mRNA medicines for infectious diseases and rare liver and respiratory diseases.

Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) has announced management participation in a Fireside Chat at the Barclays Global Healthcare Conference on March 16, 2022, at 1:35 p.m. ET. This event will provide insights into the company's late-stage clinical programs focusing on mRNA medicines, including vaccines for infectious diseases and treatments for rare liver and respiratory diseases. A live webcast will be available, with an archived replay accessible for 90 days. For more details, visit ArcturusRx.com

Arcturus Therapeutics Holdings Inc. has submitted an Emergency Use Authorization (EUA) application for ARCT-154 to the Vietnam Ministry of Health. Clinical data show 28- and 54-fold increases in neutralizing antibodies against SARS-CoV-2 ancestral and Omicron strains, respectively. Financial results for Q4 2021 reveal total revenue of $5.8 million, marking an increase from $2.2 million in Q4 2020. However, the company reported a net loss of approximately $38.7 million for the same period. Cash reserves stand at $370.5 million, expected to sustain operations into late 2023.

Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) announced the grant of stock options for 11,200 shares to three new employees as part of their employment compensation. The options, priced at $24.85 per share, are granted under the Nasdaq Rule 5635(c)(4) inducement exception. These stock options will vest over four years, with 25% vesting after one year and the rest monthly over the subsequent three years, contingent on continued employment. This move supports Arcturus's commitment to attract top talent in the competitive biotech landscape.

Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) will announce its financial results for the quarter and year ended December 31, 2021, after market close on February 28, 2022. A conference call and webcast will follow at 4:30 PM EST on the same day. The company specializes in developing mRNA medicines, focusing on vaccines for infectious diseases and rare liver and respiratory diseases. Arcturus leverages unique technologies, including LUNAR® lipid-mediated delivery and STARR™ mRNA Technology, in its diverse pipeline targeting various conditions including COVID-19 and cystic fibrosis.

Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) announced its participation in the SVB Leerink 11th Annual Global Healthcare Conference on February 18, 2022, at 12:00 PM ET. Management team members, including CEO Joseph Payne and CFO Andrew Sassine, will present a corporate overview followed by a Q&A session. Investors can register for the presentation here. A replay will be available on Arcturus’ Investor Relations website for 90 days post-event.

Arcturus Therapeutics (NASDAQ: ARCT) announced promising findings from its Phase 1/2 booster trial for mRNA vaccine candidates ARCT-154 and ARCT-165. The study demonstrated 54-fold and 47-fold increases in neutralizing antibody titers against the Omicron variant after administering low doses (5 mcg) at least five months post-initial vaccination. This data supports expanding clinical development aimed at evaluating the candidates as effective COVID-19 booster vaccines. The ongoing trial is being conducted in the U.S. and Singapore.

Arcturus Therapeutics announced positive results from its Phase 1/2 booster study of ARCT-154 and ARCT-165 vaccines. The data showed a significant 30-fold increase in neutralizing antibody concentrations against SARS-CoV-2 at Day 15, maintained at 28-fold by Day 29. Both vaccines demonstrated strong responses against various COVID-19 variants, supporting their potential as booster options. Administered as low-dose boosters, they were well-tolerated, indicating promise in ongoing clinical development.